Luspatercept
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Luspatercept |
| DrugBank ID | DB12281 |
| Brand Names (EU) | Reblozyl |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 96.32% |
Approved Indication (EMA)
Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adult
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dominant beta-thalassemia | 96.32% | DL |
| 2 | monosomy X | 96.00% | DL |
| 3 | hepatic infarction | 95.70% | DL |
| 4 | hepatic veno-occlusive disease | 94.91% | DL |
| 5 | peliosis hepatis | 94.75% | DL |
| 6 | syndrome with combined immunodeficiency | 94.28% | DL |
| 7 | pyruvate kinase deficiency of red cells | 93.84% | DL |
| 8 | thalassemia, beta+, silent allele | 93.32% | DL |
| 9 | familial apolipoprotein C-II deficiency | 93.05% | DL |
| 10 | adenosine deaminase deficiency | 92.86% | DL |
| 11 | Hb Bart’s hydrops fetalis | 92.75% | DL |
| 12 | beta-thalassemia with other manifestations | 92.61% | DL |
| 13 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | 92.34% | DL |
| 14 | partial deletion of the short arm of chromosome 16 | 92.14% | DL |
| 15 | hemolytic anemia due to glucophosphate isomerase deficiency | 91.92% | DL |
| 16 | liver angiosarcoma | 91.84% | DL |
| 17 | pyropoikilocytosis, hereditary | 91.80% | DL |
| 18 | reticular dysgenesis | 91.66% | DL |
| 19 | beta thalassemia | 91.57% | DL |
| 20 | severe combined immunodeficiency due to LCK deficiency | 91.50% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.